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Reactive oxygen species (ROS), which are both a natural
byproduct of oxidative metabolism and an undesirable
byproduct of many environmental stressors, can damage all
classes of cellular macromolecules and promote diseases
from cancer to neurodegeneration. The actions of ROS are
mitigated by the transcription factor NRF2, which regulates
expression of antioxidant genes via its interaction with cis-
regulatory antioxidant response elements (AREs). However,
despite the seemingly straightforward relationship between the
opposing forces of ROS and NRF2, regulatory precision in the
NRF2 network is essential. Genetic variants that alter NRF2
stability or alter ARE sequences have been linked to a range of
diseases. NRF2 hyperactivating mutations are associated with
tumorigenesis. On the subtler end of the spectrum, single
nucleotide variants (SNVs) that alter individual ARE se-
quences have been linked to neurodegenerative disorders
including progressive supranuclear palsy and Parkinson’s
disease, as well as other diseases. Although the human health
implications of NRF2 dysregulation have been recognized for
some time, a systems level view of this regulatory network is
beginning to highlight key NRF2-targeted AREs consistently
associated with disease.
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Many cellular challenges e chemical, metabolic, and
physical e disrupt redox homeostasis and generate
excess reactive oxygen species (ROS). ROS have the
potential to damage macromolecules including proteins,
lipids, and DNA. The latter effect is especially harmfulwww.sciencedirect.combecause it can cause DNA mutations with long-term
consequences, but significant oxidative stress can also
lead to apoptotic or necrotic cell death. Thus oxidative
damage is a significant contributor to chronic diseases,
from cancer to neurodegenerative disease [1e4]. In
response to oxidative stress, cells activate a panel of
cytoprotective genes, including antioxidant and detoxi-
fying enzymes, that counteract ROS and ROS-induced
damage to the cell. NRF2, a Cap-n-Collar (CNC) basic
leucine zipper (bZIP) transcription factor encoded by
the gene NFE2L2, is a master regulator of the tran-
scriptional response to oxidative stress [5]. NRF2 is
structurally and functionally conserved from insects to
humans, and it must dimerize with one of the three small
MAF (sMAF) bZIP proteins (MAFF, MAFG, MAFK) to
bind ARE sequences and regulate gene expression [6].
NRF2 is widely expressed, but when ROS levels are low,
nuclear NRF2 is kept low by direct interaction with the
inhibitory protein KEAP1, which sequesters NRF2 in
the cytoplasm and targets it for proteasomal degradation
[7e10]. However, ROS modify KEAP1 and impair its
ability to target NRF2 for degradation. So as ROS levels
increase (oxidative stress), KEAP1’s ability to inhibit
NRF2 decreases and nuclear NRF2 increases; the in-
crease in nuclear NRF2 drives upregulation of many
cytoprotective genes (Figure 1A) [10,11].Although gene sets necessary for responding to and
recovering from oxidative stress are key NRF2 targets,
these are not the only genes regulated byNRF2 [12e14].
The NRF2 regulatory network also contains multiple
autoregulatory loops, including a critical negative feed-
back loop: NRF2 transcriptionally activates its own
repressor, KEAP1 [14,15]. The NRF2-KEAP1 negative
feedback loop is deeply conserved, present in organisms
ranging from Drosophila to human [14,16]. This ancient
negative feedback loop highlights the importance of
keeping theNRF2pathway in check, and suggests precise
regulation of NRF2’s nuclear concentration is paramount.
The rules governing transcription factor interactions with
DNA within the nucleus are complex, but are largely a
function of transcription factor concentration and its
binding affinity for a given target DNA sequence [17,18].
Presumably, the autoregulatory loops modulating NRF2’s
nuclear concentration ensure that NRF2-ARE binding
and cis-regulatory output at all NRF2 target genes is
finely tuned for a wide range of stress conditions.
NRF2, in combination with one of the sMAF proteins,
regulates gene expression by binding ARE sequences inCurrent Opinion in Toxicology 2016, 1:71–79
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Regulatory effects of NRF2 network variation. (A) General schematic of NRF2 regulatory pathway. See text for details. (B) Mutations that disrupt
NRF2-KEAP1 interactions lead to NRF2 hyperactivation and are associated with tumorigenesis. Select NRF2 target genes are consistently upregulated
in tumors with hyperactivated NRF2. (C) Variants that disrupt individual ARE sequences create alleles with stronger ARE activity and weaker ARE activity.
Such variants can alter NRF2 target gene expression and, in some cases, disease risk.
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NRF2 network variation Lacher and Slattery 73its target genes’ enhancer or promoter regions. The ARE
is also referred to as the electrophile response element
(EpRE) or the CNC-sMAF-binding element (CsMBE)
[19,20]. Although the term ARE is more restrictive than
the latter two terms e NRF2-ARE transactivation is
responsive to more than just oxidative stress e it is the
most commonly used term for the NRF2-sMAF-binding
element. The original ARE consensus sequence was
defined as GCnnnSTCAY (where S = G or C, and
Y = C or T) [21,22]. Consistent with the consensus
motif, genome-wide NRF2 binding sites identified
using ChIP-seq (chromatin immunoprecipitation
followed by high throughput sequencing) are strongly
enriched for the sequence TGCTGAGTCAY
[12,13,23]. Thus in vivo NRF2 DNA binding is largely
driven by a higher information content version of the
original ARE consensus. The sequence identified by
ChIP-seq is functionally relevant, because both NRF2-
sMAF DNA binding (in vitro and in vivo) and NRF2-
mediated regulatory output are correlated with a
target ARE’s similarity to TGCTGAGTCAY [14,23,24].
Considering the finely tuned nature of NRF2-mediated
gene expression, it is likely that genetic variants
disrupting either controls on NRF2 nuclear concentra-
tion (Figure 1B) or NRF2-bound ARE sequences
(Figure 1C) would have significant implications for
NRF2 target gene expression. Indeed, variants of both
types have now been characterized. These variants can
have a marked effect on NRF2-mediated gene expres-
sion, and are associated with a range of pathologies.2. Trans-regulatory effects of NRF2 or
KEAP1 mutation
NRF2 activity is cytoprotective. Loss of NRF2 is
associated with genomic instability and tumorigenesis,
whereas activation of NRF2 is chemopreventive and
promotes longevity [25e27]. Yet NRF2 activation
beyond a certain threshold can be detrimental: somatic
mutations that disrupt NRF2-KEAP1 interaction pro-
mote cancer progression [28e32]. Mutations altering
either the NRF2 binding domain of KEAP1 or the
KEAP1 binding domain of NRF2 were first observed in
lung cancer [28,29,33]. Mechanistically, disruption of
protein domains at the NRF2-KEAP1 interface pre-
vents efficient targeting of NRF2 for proteasomal
degradation, which in turn leads to NRF2 accumulation
and constitutive activation of the pathway. Lung tissue
is particularly prone to NRF2 hyperactivating muta-
tions, but such mutations are also found in head and
neck squamous cell carcinomas, endometrial cancer,
and many other solid tumor types [32,34e37]. In
addition to somatic mutation, DNA hypermethylation
at the KEAP1 locus is also associated with KEAP1
repression, increased NRF2 activity, and tumorigenesis
[38e42].www.sciencedirect.comThe exact mechanisms underlying NRF2’s oncogenic
properties remain unclear, but likely involve aberrant
induction of NRF2 target genes (Figure 1B). Impor-
tantly, data from The Cancer Genome Atlas (TCGA)
indicate that mutations altering the KEAP1 binding
domain of NRF2 are associated with similar patterns of
gene upregulation across diverse tumor types (Table 1)
[43,44]. Because these gene expression changes are a
result of genetic variation at an unlinked locus (the
NFE2L2 gene), they represent the trans-effects of mu-
tations at NFE2L2. Many of the upregulated genes are
near genomic regions bound by NRF2 based on human
ChIP-seq data, so these presumably represent direct
NRF2 targets (Table 1).
Oncogenic NRF2 provides a selective advantage to cells
across diverse tissue environments, and the TCGA data
demonstrate that it also casts a transcriptional shadow
that is relatively consistent across these environments.
Thus it is likely that subsets of the consistently upre-
gulated genes are responsible for the metabolic, prolif-
erative, and chemoresistance advantages afforded to
cells with constitutive NRF2 activity. Multiple genes in
Table 1 represent high priority candidates. For example,
NRF2 targets necessary for generating the antioxidants
glutathione and thioredoxin are consistently overex-
pressed in NRF2 gain-of-function tumors, and both
antioxidants are essential for cancer initiation and pro-
gression [45]. Synthesis and regeneration of glutathione
is largely controlled by the catalytic and modifier sub-
units of the glutamate-cysteine ligase enzyme (encoded
by GCLC and GCLM, respectively), the cysteine trans-
porter subunit encoded by SLC7A11, and glutathione
reductase (encoded by GSR). Thioredoxin activity is
induced by expression of TXN, which codes for this
antioxidant, and regenerated by thioredoxin reductase
(encoded by TXNRD1). But antioxidant genes are not
the only group of NRF2 targets with potential cancer
relevance. Upregulation of enzymes in the pentose
phosphate pathway, including 6-phosphogluconate dehy-
drogenase (PGD), glucose-6-phosphate dehydrogenase
(G6PD), transaldolase (TALDO1), and transketolase (TKT),
drives metabolic reprogramming and NRF2-dependent
proliferation in lung adenocarcinoma cells (A549) and
other cell lines [46,47]. Additionally, a number of the
NRF2 targets that are repeatedly induced in cancer
likely promote chemoresistance by increasing drug
metabolism (ALDH3A1, NQO1, AKR1C1, EPHX1) or
transport (ABCB6) [48]. Combined, the genes that are
consistently responsive to NRF2 activity in diverse
tissue contexts can explain much of NRF2’s oncogenic
potential.
The molecular profile of oncogenic NRF2 hyper-
activation, at least with regard to gene expression signa-
tures, is largely independent of a tumor’s tissue of origin.
The upregulated genes in NRF2-driven cancer areCurrent Opinion in Toxicology 2016, 1:71–79
Table 1 Genes consistently upregulated in tumors with hyperactivated NRF2. Bold genes are direct NRF2 targets based on human
ChIP-seq data [13,14]. Non-bold genes are direct NRF2 targets based on additional experimental evidence [48]. “Additional genes” are
those with little evidence for direct regulation by NRF2. Tumor expression data are from [43]. Tumor type abbreviations: B = Bladder
Urothelial Carcinoma; H = Head–Neck Squamous Cell Carcinoma; L = Lung Squamous Cell Carcinoma; U = Uterine Corpus Endometrial
Carcinoma.
Gene symbol Gene name Tumor type
Upregulated in 4/4 NRF2 hyperactivated tumor types:
ABCB6 ATP binding cassette subfamily B member 6 B, H, L, U
ALDH3A1 Aldehyde dehydrogenase 3 family member A1 B, H, L, U
FECH Ferrochelatase B, H, L, U
GCLM Glutamate-cysteine ligase, modifier subunit B, H, L, U
ME1 Malic enzyme 1 B, H, L, U
NQO1 NAD(P)H quinone dehydrogenase 1 B, H, L, U
PGD Phosphogluconate dehydrogenase B, H, L, U
SRXN1 Sulfiredoxin 1 B, H, L, U
TALDO1 Transaldolase 1 B, H, L, U
TKT Transketolase B, H, L, U
TXNRD1 Thioredoxin reductase 1 B, H, L, U
OSGIN1 Oxidative stress induced growth inhibitor 1 B, H, L, U
AKR1C1 Aldo-keto reductase family 1 member C1 B, H, L, U
EPHX1 Epoxide hydrolase 1 B, H, L, U
G6PD Glucose-6-phosphate dehydrogenase B, H, L, U
Additional genes: AKR1B10, AKR1C2, AKR1C3, CABYR, CES1, CYP4F3, JAKMIP3, PANX2, TRIM16L
Upregulated in 3/4 NRF2 hyperactivated tumor types:
GCLC Glutamate-cysteine ligase catalytic subunit B, H, U
GSR Glutathione reductase B, H, L
PRDX1 Peroxiredoxin 1 B, H, L
SLC7A11 Solute carrier family 7 member 11 B, H, L
TXN Thioredoxin B, H, L
PTGR1 Prostaglandin reductase 1 B, H, L
Additional genes: AGPAT9, CBR3, CES4, CLDN8, CYP4F11, FTHL3, KIAA0319, MAP2, MDGA1, NAMPT, RBM19, RIT1, SAMD5, SPP1, TDP2,
TSPAN7, WNT5A
Upregulated in 2/4 NRF2 hyperactivated tumor types:
ABHD4 Abhydrolase domain containing 4 H, L
ADAM17 ADAM metallopeptidase domain 17 B, L
COA6 Cytochrome c oxidase assembly factor 6 B, L
FTH1 Ferritin heavy chain 1 H, U
KEAP1 Kelch like ECH associated protein 1 B, L
MAF-G MAF bZIP transcription factor G B, L
PIR Pirin B, U
SLC12A8 Solute carrier family 12 member 8 H, L
SLC3A2 Solute carrier family 3 member 2 B, L
TLK1 Tousled like kinase 1 H, L
TMTC3 Transmembrane and tetratricopeptide repeat containing 3 B, L
ZNF746 Zinc finger protein 746 B, L
ABCC1 ATP binding cassette subfamily C member 1 B, H
ABCC3 ATP binding cassette subfamily C member 3 H, L
ADH7 Alcohol dehydrogenase 7 B, L
CBR1 Carbonyl reductase 1 B, H
GPX2 Glutathione peroxidase 2 H, L
IDH1 Isocitrate dehydrogenase 1 H, L
PRDX6 Peroxiredoxin 6 H, L
Additional genes: ABCA4, ADAM23, AKR1B15, ANXA10, ASF1A, ASPH, C14orf149, CREG1, DNAJB4, EPS8, EPT1, ETFB, FAM190A, FBXO30,
GLI2, GSTM3, GSTM4, HHIPL2, LOC729082, MAP1B, MEGF9, NECAB2, NSUN3, PHEX, PHKB, RAP1GAP, RNF217, SLC47A2, SLC9A3R1,
SMOC2, SOST, TNPO1, TPD52L1, TRIM16, TSKU, UGT1A7
74 Oxidative Toxicologyresponsible for many of NRF2’s core cytoprotective
functions in non-pathological situations, so itmakes sense
that they can be activated in many cell types. Never-
theless, what mechanistically differentiates this signifi-
cant subset ofNRF2-targeted AREs from its other targetsCurrent Opinion in Toxicology 2016, 1:71–79remains unclear. At the cancer-induced AREs, NRF2
binding and transactivation is ostensibly not inhibited by
other tissue-specific regulatory networks (transcriptional
repressors, chromatin environment, etc.), and this lack of
constraint can have dire consequences.www.sciencedirect.com
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Genetic variants that disrupt individual NRF2-targeted
ARE sequences are expected to have more specific ef-
fects than variants that alter overall levels of nuclear
NRF2. Whereas disruption of overall NRF2 levels im-
pacts many genes in the network (Table 1), a cis-regu-
latory ARE variant will primarily alter expression of the
gene regulated by the ARE (Figure 1C). Although the
effects of cis-regulatory variation are more precise, they
are not without biological consequence. Most disease-
associated variants identified by genome-wide associa-
tion studies (GWAS) fall in non-protein coding DNA.
Most of the non-coding disease-associated variants are
innocuous e they simply reach significance because
they are co-inherited with a functional variant e but
those with functional relevance often disrupt tran-
scription factor binding sites [49e51]. This is indeed
the case for NRF2: polymorphic ARE motifs have
recently been linked to allele-specific enhancer activity,
gene expression, and disease risk [24,52].
A position weight matrix scanning approach identified
over two million ARE sequences in the human genome,
but NRF2 and sMAF ChIP-seq data suggest that less
than 2% are functional AREs [52]. This is consistent
with numbers observed for other human transcription
factors [18,53]. Approximately 7.5% (2689 out of
35,659) of the AREs consistently bound by NRF2 and/Table 2 Disease-associated, ARE-disrupting single nucleotide
represented are those falling within 2 base pairs of an ARE containing
(PWM) match score >10. For the ARE Sequences column, SNVs are u
stronger PWM match is highlighted red, and the weaker PWM match is
Project.
SNP ID ARE sequence Allele frequency
rs242561 0.90
0.10
rs241032 0.57
0.43
rs6426833 0.59
0.41
rs17035378 0.52
0.48
rs369184 0.85
0.15
rs4818832 0.64
0.36
Additional high priority polymorphic AREs: rs6426519, rs9603754, rs9884209,
www.sciencedirect.comor sMAFs contain a potential ARE-altering single
nucleotide variant (SNV), and 14 of the variable AREs
are in linkage disequilibrium (i.e., co-inherited) with
disease-associated variants identified by GWAS [52].
Disease-associated, variant AREs represent instances
where cis-regulatory variation in the NRF2 network
might have a phenotypic impact (disease risk); a subset
of these ARE-altering SNVs are outlined in Table 2. A
connection to cancer is still evident: two polymorphic
AREs are associated with testicular germ cell tumors.
However variant AREs are also linked to disease beyond
cancer. Interestingly, the list includes hits for neuro-
degenerative disorders including progressive supra-
nuclear palsy (PSP), Parkinson disease (PD), and
corticobasal degeneration, as well as gastrointestinal
disorders including celiac disease and colitis. These
disease associations are based on common germline
SNVs (minor allele frequency greater than 1%), but rare
inherited variants that disrupt AREs could also be
important [24].
One ARE-altering SNV, rs242561, falls within an NRF2-
bound ARE at theMAPT locus [52]. The major allele of
rs242561 creates a mismatch ARE (CGCTGAGTCAC
e variant sequence is underlined) and the minor allele
creates a perfect ARE (TGCTGAGTCAC). Thus, most
people carry one or two copies of a mismatch NRF2-
targeted ARE in a MAPT enhancer region. A smallervariants. Summary of significant SNVs identified in [52]. SNVs
the GCnnnnTCA core sequence, and with a position weight matrix
nderlined and highlighted in red/blue – the variant that generates a
highlighted blue. Allele frequency data are from the 1000 Genomes
Nearest gene Disease association(s)
MAPT Progressive Supranuclear Palsy;
Parkinson’s Disease; Corticobasal
Degeneration; Interstitial Lung Disease
CRHR1-IT1 Parkinson’s Disease
RNF186 Ulcerative Colitis
PLEK Celiac Disease
TEX14 Testicular Germ Cell Tumor
YBEY Testicular Germ Cell Tumor
rs12638492, rs13067040, rs16857611, rs62033400, rs62094906
Current Opinion in Toxicology 2016, 1:71–79
76 Oxidative Toxicologysubset of the population carries a perfect-match ARE at
this MAPT enhancer. MAPT encodes the protein tau,
which plays a central role in multiple neurodegenerative
diseases, and rs242561 is in linkage disequilibrium with
variants associated PSP, PD, and corticobasal degener-
ation [54e56]. Importantly, the minor allele of rs242561
(perfect-match ARE) is associated with decreased risk
of all three aforementioned neurodegenerative disor-
ders, acts as a hypermorphic ARE in reporter assays, and
is associated with increased expression of a protective
isoform of MAPT [52,57e59]. Although it is possible
that additional non-coding variants affect MAPT
expression and neurodegenerative disease risk, these
data suggest that the ARE impacted by rs242561 plays a
significant functional role at this locus.
The above example suggests that inherited variation in
specific NRF2-targeted ARE sequences can influence
gene expression and, ultimately, disease risk. However,
somatic variation in ARE sequences might also have an
impact on disease. Cancer genome sequencing data
from TCGA indicate that somatic variants disrupting
ARE-like sequences are under positive selection in
cancer cells [60]. This intriguing finding places the ARE
among a small subset of transcription factor binding
motifs commonly mutated in cancer. Thus, ARE muta-
tions and aberrant expression of select NRF2 target
genes are also likely to play an important functional role
in cancer.
When considering the effects of ARE variation, one
must consider that our current models of NRF2 DNA
binding and regulatory output are incomplete. Identi-
fication of ARE sequences are dependent on model
used (position weight matrix or other models). Some
models focus on the core ARE sequence described
above, while others include significant stretches of
flanking sequence e both may be functionally relevant.
In addition, there are many variant AREs associated
with gene expression changes that have not yet been
linked to a disease phenotype (SL and MS, not shown).
It is likely that many of these changes are not strong
enough to have a phenotypic impact; however some
may be revealed as important in future disease associ-
ation studies.
It is also important to recognize that ARE activity is
context-dependent. That is, ARE activity generally in-
creases under various stress conditions. Therefore the
cis-regulatory effects of some ARE variants might only be
evident under conditions where AREs are active.
Oxidative stress, from both exogenous and endogenous
sources, is an early and ongoing contributor to many
diseases, so it makes sense that some variant AREs will
appear significant in standard disease association
studies. This explanation holds for rs242561, as oxida-
tive stress plays a significant role in the pathology of
neurodegenerative diseases such as PD and PSP [61eCurrent Opinion in Toxicology 2016, 1:71–7964]. However, certain ARE variants may only display
significant disease associations in the presence of other
genetic variants or environmental stressors that disrupt
redox homeostasis. GWAS are become increasingly
expansive, allowing for exploration of gene-gene and
gene-environment interactions, so it is possible that
additional disease-associated ARE variants will be
identified in future studies.4. A role for additional ARE binding
proteins?
Precise regulation of NRF2-ARE binding is clearly
important. Nuclear NRF2 concentration and ARE
quality (i.e., similarity to sequence TGCTGAGTCAY)
are significant contributors to this protein-DNA inter-
action, however additional variables must be considered.
NRF2 is part of a family of CNC transcription factors, all
with very similar DNA binding properties. Mammalian
genomes contain six CNC proteins: four transcriptional
activators (NFE2, NRF1, NRF2, NRF3), and two re-
pressors (BACH1, BACH2) [5]. With the exception of
NFE2, which regulates developmental transitions in the
hematopoietic system [65e67], all CNC factors have
been implicated as regulators of stress responsive genes
[5]. And like NRF2, the other CNC proteins all
dimerize with sMAF proteins, and all bind ARE se-
quences to regulate gene expression [6].
Compared to NRF2, less is known about the other four
stress responsive CNC factors. All are expressed in a
variety of cell types except for BACH2, which is most
prevalent in the brain and B cells [5]. Current models of
CNC mediated gene expression posit that regulatory
output at an ARE is the result of competition between
activator and repressor CNC factors, with activator CNC
factors dominating in stress conditions [68e72]. How-
ever, this competition model is based largely on the
opposing actions of NRF2 and BACH1 at AREs associ-
ated with two canonical antioxidant genes (NQO1 and
HMOX1), and may not apply equally to all CNC target
genes [68,71,73]. Further complicating matters, non-
CNC proteins can also modulate ARE activity. The
ARE, like all cis-regulatory sequences, can be repressed
by nucleosomes, which hinder transcription factor
access to a binding motif. ARE-like motifs can also be
directly repressed by MAF homodimers [74] (see for a
[75] comprehensive review). Additionally, stress
responsive AP-1 protein complexes, which consist of
heterodimers of proteins from the FOS, JUN, and ATF
families, bind a target sequence very similar to the ARE
[76].
A complete understanding of NRF2-mediated gene
regulation must take additional ARE-binding factors
into account (Figure 2). Models that integrate cooper-
ation and competition for ARE binding among the
activating and repressive factors will certainly furtherwww.sciencedirect.com
Figure 2
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NRF1-MAF
NRF2-MAF
NRF3-MAF
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BACH1-MAF
BACH2-MAF
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Nucleosomes
Repressors
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(Stress)
Potential ARE-binding transcription factor complexes. Current
models suggest ARE regulatory output is driven by competition between
activator and repressor CNC-MAF proteins. The impact of additional ARE
binding proteins and nucleosomes, and whether this model extends
equally to a wide range of functional AREs, remains unclear.
NRF2 network variation Lacher and Slattery 77our understanding of the normal, homeostatic functions
of NRF2. More comprehensive models might also
explain why only a subset of AREs is consistently
misregulated in cancer, or why some ARE-disrupting
SNVs affect disease risk while others do not. The ge-
nomics era has yielded tremendous insights into NRF2
biology. Approaches that view NRF2 in the context of
additional ARE-binding factors, and integrate with dis-
ease related functional genomics data (e.g., TCGA and
GWAS data), will provide a comprehensive view of the
regulatory mechanisms at play in this network in both
physiological and pathological contexts.
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